Sichuan Biokin Stock Hits Day Low Amid Price Pressure, Closes at CNY 253.69

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.09% on March 26, 2026. The stock reached an intraday low of CNY 253.69, reflecting ongoing challenges within the company. Over the past week, the stock has decreased by 5.34%, and its performance over the last month shows a decline of 7.66%. Despite a year-to-date performance of -21.08%, Sichuan Biokin has managed to achieve a 23.12% increase over the past year, outperforming the China Shanghai Composite, which recorded a 15.45% gain. However, the company has faced significant financial hurdles, reporting negative net sales growth of 63.52% and a net profit decline of 112.34% over the last nine months. The operating cash flow has also reached a low of CNY -2,331.46 million, indicating liquidity concerns. With a market capitalization of CNY 29,530 million, Sichuan Biokin operates in the pharmaceuticals and biotechnology sector, but its current financial metrics suggest a challenging environment ahead.